|
Amaethon was formed through three organisations sharing our
vision for the development of an innovative approach to creating value
from research and intellectual property generated within an academic
environment.
CNAP is the research centre
based in the biology department at the
University
of York for which we have exclusive commercialisation rights until 2028.
IP2IPO is the
AIM
listed intellectual property business that has invested in our company,
receiving a one third equity stake, and has also created a dedicated
seed capital fund for investing in spin-outs we identify from the CNAP
research.
The
University
of York
is the legal entity that owns the intellectual property created within
CNAP and is a two thirds shareholder in our company.
Our partners work closely with us to achieve our objective of
establishing Amaethon as a world leading technology commercialisation
company focusing upon gene discovery research and the utilisation of
plants and microbes as cell factories. |
